|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Yvonne_Greenstreet
|
|
gptkbp:collaboratesWith
|
gptkb:Sanofi
gptkb:Novartis
gptkb:Regeneron_Pharmaceuticals
gptkb:Vir_Biotechnology
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
02043Q107
|
|
gptkbp:focusArea
|
cardiometabolic diseases
central nervous system diseases
hepatic infectious diseases
rare genetic diseases
|
|
gptkbp:foundedYear
|
2002
|
|
gptkbp:founder
|
gptkb:John_Maraganore
|
|
gptkbp:fullName
|
gptkb:Alnylam_Pharmaceuticals,_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALNY
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US02043Q1076
|
|
gptkbp:marketCap
|
over $20 billion (as of 2024)
|
|
gptkbp:notableInvention
|
RNAi therapeutics platform
|
|
gptkbp:numberOfEmployees
|
~1900
|
|
gptkbp:product
|
gptkb:AMVUTTRA
gptkb:GIVLAARI
gptkb:ONPATTRO
gptkb:OXLUMO
|
|
gptkbp:specializesIn
|
RNA interference therapeutics
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:NASDAQ_Biotechnology_Index
gptkb:Russell_1000
gptkb:S&P_400
|
|
gptkbp:stockSymbol
|
gptkb:ALNY
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:ALNY
|
|
gptkbp:website
|
https://www.alnylam.com/
|
|
gptkbp:bfsParent
|
gptkb:NASDAQ:_ALNY
gptkb:Alnylam_Pharmaceuticals_IPO
|
|
gptkbp:bfsLayer
|
7
|